- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 11.02. | Prenetics Global Limited: Nasdaq-Listed Prenetics Announces Genomics-Based Partnership with Humanity Protocol and Launches Crypto Strategic Reserve | 1 | GlobeNewswire (USA) | ||
| 15.01. | Prenetics Global Limited: Prenetics' IM8 Achieves Prestigious NSF Certified for Sport for Daily Ultimate Essentials | 1 | GlobeNewswire (USA) | ||
| 13.12.24 | Prenetics Global Ltd - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 05.12.24 | Prenetics Global Limited: Prenetics' IM8 and University of Oxford Begin Groundbreaking Space Experiment to Study Accelerated Aging and Longevity on the ISS with SpaceX, Supported by Space Applications Services | 1 | GlobeNewswire (USA) | ||
| 27.11.24 | Prenetics Global Q3 Loss Narrows On Surge In Revenue | - | RTTNews | ||
| 27.11.24 | Prenetics Global: Q3 Earnings Insights | 1 | Benzinga.com | ||
| 27.11.24 | Prenetics Global Limited: Prenetics Announces Third Quarter 2024 Financial Results | 339 | GlobeNewswire (Europe) | Revenue Grew 59.4% to $7.8 million from Prior Year and 30.9% Sequentially Officially Launched IM8Health.com, a new premium supplements brand Tencent Invests $30 million in Insighta's Early Cancer... ► Artikel lesen | |
| 27.11.24 | Prenetics Global Ltd - 6-K, Report of foreign issuer | - | SEC Filings | ||
| PRENETICS GLOBAL Aktie jetzt für 0€ handeln | |||||
| 18.11.24 | Prenetics Global Limited: Nasdaq-Listed Prenetics and David Beckham Officially Launch IM8 Health | 2 | GlobeNewswire (USA) | ||
| 15.10.24 | Prenetics Global Ltd - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 11.10.24 | Prenetics Global GAAP EPS of -$1.58, revenue of $5.9M | 4 | Seeking Alpha | ||
| 07.10.24 | Prenetics Global Ltd - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 07.10.24 | Prenetics Global Limited: Prenetics Announces Second Quarter 2024 Financial Results | 430 | GlobeNewswire (Europe) | Cost Optimization Boosted Gross Margin by 21.7% YoY in H1 2024Enters U.S. Health Market in October with IM8, a New Health and Wellness BrandRe-affirms Revenue Target to Exceed US$33 million for FY... ► Artikel lesen | |
| 27.09.24 | Prenetics Global Ltd - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 16.09.24 | Prenetics Global Ltd - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 11.07.24 | Prenetics Global Limited: Prenetics, NASDAQ Health Sciences Company, Partners with David Beckham | 430 | GlobeNewswire (Europe) | Beckham becomes a strategic investor in PreneticsBeckham and Prenetics are co-founding partners for IM8, a new health and wellness brand LOS ANGELES, July 11, 2024 (GLOBE NEWSWIRE) -- Prenetics... ► Artikel lesen | |
| 18.06.24 | Prenetics Global Limited: Prenetics Announces First Quarter 2024 Financial Results | 202 | GlobeNewswire (Europe) | First Quarter Revenue Increased 30.2% and Gross Profit Increased 159.8% from Prior Year Quarter Confirms Strategic Pivot Targeting the U.S. Consumer Healthcare Market Reaffirms 2024 Revenue Range... ► Artikel lesen | |
| 01.04.24 | Prenetics Global Limited: Prenetics Announces Fourth Quarter and Full Year 2023 Financial Results | 261 | GlobeNewswire (Europe) | HONG KONG, April 01, 2024 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) ("Prenetics" or the "Company"), a leading genomics-driven health sciences company, today announced unaudited financial... ► Artikel lesen |
18 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QUANTUM-SI | 1,710 | 0,00 % | Quantum-Si Incorporated: Quantum-Si Showcases Advances in Multiomics at the Festival of Genomics UK | Quantum-Si Incorporated (Nasdaq: QSI) ("Quantum-Si," "QSI" or the "Company"), The Protein Sequencing Company, announces its participation in the upcoming Festival of Genomics UK, taking place on... ► Artikel lesen | |
| SCILEX | 0,329 | 0,00 % | SCLX-Aktie fällt auf 52-Wochen-Tief von 0,33 US-Dollar | ||
| TEMPUS AI | 68,13 | 0,00 % | Tempus AI Aktie: Langfristige Planung vorgestellt | Der Technologiekonzern Tempus AI verzeichnet derzeit bemerkenswerte Bewegungen im Aktienhandel, wobei mehrere hochrangige Führungskräfte in der vergangenen Woche umfangreiche Aktienverkäufe tätigten.... ► Artikel lesen | |
| HARMONY BIOSCIENCES | 34,560 | 0,00 % | Harmony Biosciences price target cut to $42 at Mizuho | ||
| ARVINAS | 17,770 | -3,27 % | Arvinas Inc.: Arvinas Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update | - Announced that topline data from the monotherapy Phase 3 VERITAC-2 trial is anticipated in 1Q25 - - Presented Phase 1b data from the TACTIVE-U sub-study of vepdegestrant in combination with... ► Artikel lesen | |
| EVOTEC | 8,715 | +2,29 % | Evotec-Aktie kann Vortagsniveau nicht halten (8,49 €) | An der deutschen Börse liegt die Evotec-Aktie derzeit im Minus. Der jüngste Kurs betrug 8,49 Euro. Am Aktienmarkt liegt die Evotec-Aktie aktuell im Minus. Das Wertpapier verbilligte sich um 24 Cent.... ► Artikel lesen | |
| QIAGEN | 38,005 | +1,69 % | BERENBERG stuft QIAGEN NV auf 'Buy' | HAMBURG (dpa-AFX Analyser) - Die Privatbank Berenberg hat das Kursziel für Qiagen von 54,90 auf 48,00 Euro gesenkt und die Einstufung auf "Buy" belassen. Das vierte Quartal sei solide gewesen, auch... ► Artikel lesen | |
| DYNE THERAPEUTICS | 14,010 | 0,00 % | Dyne Therapeutics SVP Richard Scalzo verkauft Aktien im Wert von 34.707 US-Dollar | ||
| RECURSION PHARMACEUTICALS | 9,265 | 0,00 % | Recursion Pharmaceuticals, Inc. (RXRX): The Best Performing Pharma Stock So Far in 2025? | ||
| SPRINGWORKS THERAPEUTICS | 58,24 | 0,00 % | Merck KGaA: Wechsel im Top-Management - wann schlägt der DAX-Konzern bei SpringWorks zu? | Die Aktie von Merck KGaA notiert weiterhin in der Nähe des 52-Wochen-Tiefs. Das bestätigte Übernahmeinteresse an SprinWorks Therapeutics hat den DAX-Wert jüngst unter Druck gesetzt, denn die Marktteilnehmer... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 36,810 | 0,00 % | Kymera Therapeutics, Inc.: Kymera Therapeutics Outlines Key 2025 Objectives and Strategy to Advance Industry Leading Portfolio of Oral Immunology Programs | KT-621 (STAT6) Phase 1 healthy volunteer trial ongoing, with data expected in 2Q25 Kymera plans to initiate a KT-621 Phase 1b trial in atopic dermatitis (AD) patients in 2Q25 with data in 4Q25 and... ► Artikel lesen | |
| DAY ONE BIOPHARMACEUTICALS | 12,430 | 0,00 % | Day One Biopharmaceuticals, Inc.: Day One Reports Third Quarter 2024 Financial Results and Corporate Progress | Achieved $20.1 million in OJEMDATM (tovorafenib) net product revenue Ended the third quarter with $558.4 million in cash, cash equivalents and short-term investments Company to host conference call... ► Artikel lesen | |
| DISC MEDICINE | 54,53 | 0,00 % | Disc Medicine Inc: Disc Medicine Announces Successful Type C Meeting with FDA for Bitopertin in Erythropoietic Protoporphyria (EPP) and Shares Plans for NDA Submission | Pursuing accelerated approval for bitopertin in EPP with protoporphyrin IX (PPIX) reduction as the surrogate endpointPlanning to submit NDA under accelerated approval pathway in H2 2025 based on existing... ► Artikel lesen | |
| ABSCI | 4,960 | 0,00 % | Absci Corporation: Absci and AMD Announce Collaboration and Strategic Investment to Accelerate the Future of AI Drug Discovery | VANCOUVER, Wash., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ: ABSI), a data-first generative AI drug creation company, today announced a strategic collaboration with AMD to deploy... ► Artikel lesen | |
| BEAM THERAPEUTICS | 30,440 | 0,00 % | Why Beam Therapeutics Inc. (BEAM) is the Best Performing Pharma Stock So Far in 2025 |
PRENETICS GLOBAL LIMITED gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 5,350 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PRENETICS GLOBAL LIMITED finden Sie auf Wallstreet Online.
